Navigation Links
Anthera Announces Completion of Safety Review by DSMB for VISTA-16
Date:12/14/2011

(atorvastatin calcium) to reduce secondary Major Adverse Cardiovascular Events in patients who have recently experienced an Acute Coronary Syndrome. In February 2010, Anthera received a SPA from the U.S. FDA for the VISTA-16 Phase 3 study for the use of varespladib in treating high-risk ACS patients.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has three late stage clinical products: varespladib methyl (A-002), A-001 and blisibimod (A-623). Varespladib methyl (A-002) and A-001 are designed to inhibit a novel enzyme target known as secretory phospholipase A2 (sPLA2). Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. Blisibimod targets elevated levels of B-lymphocyte stimulator (BAFF) which have been associated with a variety of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus (lupus) and rheumatoid arthritis.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including A
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals Promotes Dr. Debra Odink to Chief Technology Officer
2. Anthera Pharmaceuticals Reports 2011 Third Quarter Financial Results and Operational Update
3. Anthera Announces Last Patient Enrolled in PEARL-SC Study
4. Anthera Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application Covering A-002 Plus Statin Compositions
5. Anthera Pharmaceuticals Reports 2011 Second Quarter Financial Results and Operational Update
6. Anthera Pharmaceuticals Announces Completion of Public Offering of Common Stock
7. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
8. Anthera Pharmaceuticals Reports 2011 First Quarter Financial Results and Operational Update
9. Anthera Pharmaceuticals Successfully Completes Interim Biomarker Analysis of VISTA-16 Study and Third Safety Review of Varespladib Methyl
10. Anthera Announces Conference Call to Discuss Analytical Method and Timing of Upcoming VISTA-16 Biomarker Analysis
11. Anthera Pharmaceuticals Names Lawrence Rosania as Vice President of Global Regulatory Affairs and Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 Research ... addition of the "Immunoprotein Diagnostic Testing Market ... the highest CAGR of 6% and is expected ... report to their offering. ... immunoprotein diagnostic testing has been segmented according to ...
(Date:7/11/2014)... Neurelis, Inc. ("Neurelis") today announced an agreement ... held by Biotie to purchase Neurelis, clearing the way ... diazepam) for pediatric and adult epilepsy patients who experience ... Biotie has advanced the development program for NRL-1 and ... work required for NDA submission to the FDA.  Given ...
(Date:7/10/2014)... , July 10, 2014  The U.S. Department ... three-year grant to University Hospitals (UH) Case Medical Center ... new national model aimed at improving care for patients ... Care," the project will test a unique model developed ... with late-stage disease, significant comorbidities, or demonstrated need for ...
Breaking Medicine Technology:Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2Neurelis Regains Rights to Intranasal Diazepam Program 2Neurelis Regains Rights to Intranasal Diazepam Program 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... BEACH, Calif., Jan. 25, 2011 Every business needs a ... others use a differentiation advantage. Hospitals are not immune from ... Dr. Barry Friedberg says if hospitals want ... institute the use of a brain monitor in all surgeries ...
... an innovative medical technology company focused on the treatment ... Relations, LLC of Bridgewater, N.J., as its public relations ... for the Aerocrine brand; most immediately surrounding the NIOX ... available to measure exhaled nitric oxide (eNO) to aid ...
Cached Medicine Technology:If Hospitals Want a Competitive Advantage - Use Brain Monitors in Surgeries Requiring Sedation says Renowned Anesthesiologist 2R&J Public Relations Named Agency of Record for Aerocrine, Inc. 2
(Date:7/11/2014)... July 11, 2014 (HealthDay News) -- Children who ... risk for complications and potentially even death than ... new study. However, the Johns Hopkins researchers ... The researchers analyzed data on nearly 440,000 ... States underwent over a 22-year period. The ...
(Date:7/11/2014)... Stamford, CT (PRWEB) July 11, 2014 ... – the nation’s only non-profit dedicated exclusively to ... announced that Joshua Corday has joined the organization ... veteran fundraising professional with deep experience securing gifts ... he served as Annual Giving Director for NewYork ...
(Date:7/11/2014)... Presently, disposable medical suppliers call for the biggest ... During the past two decades, the world market for ... 12.5% per year), primarily owing to the importance of ... the largest market for disposable medical supplies in the ... position is held by Europe with a 29% market ...
(Date:7/11/2014)... has found that organic foods and crops have ... including more antioxidants and fewer, less frequent pesticide ... 343 peer-reviewed publications comparing the nutritional quality and ... fruits, vegetables, and grains. The study team applied ... and non-organic foods. , "Science marches on," ...
(Date:7/11/2014)... 2014 (HealthDay News) -- Prostate cancer patients are more ... effective treatment and die sooner if they also have ... from more than 41,200 American men who were diagnosed ... followed them through 2009. Nearly 1,900 of the patients ... before their prostate cancer was discovered. "Men with ...
Breaking Medicine News(10 mins):Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 2Health News:Alliance for Cancer Gene Therapy (ACGT) Welcomes Joshua Corday as Senior Development Officer 3Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Major study documents nutritional and food safety benefits of organic farming 2Health News:Major study documents nutritional and food safety benefits of organic farming 3Health News:Depression May Make It Harder to Beat Prostate Cancer 2
... important regulatory enzyme may slow the loss of brain ... disorders. In a report receiving advance online publication ... (MGH)-based research team reports that increased expression of Sirt1, ... the brain of a mouse model of HD protected ...
... a dentist but not a general healthcare provider, according to an ... Health . The study, conducted by a nursing-dental research team ... proportion of Americans who are seen annually by a dentist but ... suggests dentists can play a crucial role as health care practitioners ...
... Reporter , FRIDAY, Dec. 16 (HealthDay News) -- Not only does ... in their quality of life, new research finds. ... are a lot of benefits that you might not have thought ... you,d have more stress, that quitting would put more stress on ...
... for the treatment of breast cancer has been ... the U.S. as an alternative to standard whole-breast ... 16th in the Journal of the ... APBI recurrence (external beam radiation, intraoperative radiotherapy, brachytherapy ...
... , FRIDAY, Dec. 16 (HealthDay News) -- First responders ... than double the rate of the general U.S. population, new ... 8 in the American Journal of Industrial Medicine , ... the result of their exposure to the toxic dust created ...
... Road Rippers Lightning Rods, Let,s Rock Elmo and the I ... season, parents should ensure that their children don,t risk permanent ... Department of Otolaryngology measured the noise levels of two dozen ... precise gauging in a soundproof booth at UC Irvine Medical ...
Cached Medicine News:Health News:Regulatory enzyme overexpression may protect against neurodegeneration in Huntington's disease 2Health News:NYU study concludes that dentists could screen 20 million Americans for chronic physical illnesses 2Health News:Life After Cigarettes Is Happier: Study 2Health News:Life After Cigarettes Is Happier: Study 3Health News:Advantages and motivations uncertain behind use of brachytherapy for breast cancer radiotherapy 2Health News:Advantages and motivations uncertain behind use of brachytherapy for breast cancer radiotherapy 3Health News:WTC First Responders More Likely to Have Asthma: Study 2Health News:UC Irvine researchers urge caution when buying noisy toys 2
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. Depth: 500 to 700....
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. Depth: 500 to 600....
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. Depth: 550 to 700....
The Astigmatome makes precise and accurate cuts for astigmatism correction simply and safely. Depth: 500 to 700....
Medicine Products: